13F Holdings
中文EN

MESO MESOBLAST LTD IFRS

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1345099 · Fiscal year ends 06/30

Financial factors as of 2025-06-30 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY191.4%
TTM net income YoY-16.1%
TTM EPS YoY5.1%
Revenue 3-yr CAGR19.0%
Net income 3-yr CAGR—

Margins

Gross margin70.2%
Operating margin—
Net margin-593.9%
FCF margin-294.4%
EBITDA margin—

Returns

ROE-19.0%
ROA-14.1%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets23.9%
Debt / equity0.20x
Current ratio1.99x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.49x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue4.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-06-30FY20242024-06-30FY20232023-06-30FY20222022-06-30FY20212021-06-30
Income statement
Revenue$17.20M$5.90M$7.50M$10.21M$7.43M
Cost of revenue$5.13M$0$0——
Gross profit$12.07M$5.90M$7.50M——
R&D expense$34.81M$39.72M$52.82M$32.81M$53.01M
SG&A expense$39.31M$24.98M$27.48M——
Interest expense$21.75M$20.66M$19.44M$16.91M$15.94M
Pretax income-$101.81M-$88.15M-$82.10M-$91.59M-$99.63M
Income tax$330,000-$191,000-$212,000-$239,000-$819,000
Net income-$102.14M-$87.96M-$81.89M-$91.35M-$98.81M
EPS (basic)-0.08-0.09-0.11-0.13-0.16
EPS (diluted)-0.08-0.09-0.11-0.13-0.16
Weighted avg. shares (diluted)1.21B986.70M777.72M682.86M605.06M
Balance sheet
Cash & equivalents$161.55M$62.96M$71.32M$60.45M$136.88M
Receivables$14.87M$20.95M$7.00M$4.40M$4.84M
Inventory$22.25M$0———
Current assets$204.35M$86.46M$81.66M$69.84M$148.23M
PP&E, netmay include right-of-use assets (IFRS)$1.70M$1.11M$1.36M$2.04M$3.02M
Total assets$784.68M$669.15M$669.41M$662.14M$744.72M
Current liabilities$102.63M$73.24M$41.98M$51.37M$94.27M
Short-term debt$54.16M$13.86M$5.95M$5.02M$53.20M
Long-term debt$67.74M$100.48M$102.81M$91.62M$41.05M
Total debt$121.89M$114.34M$108.76M$96.63M$94.25M
Total liabilities$187.24M$188.80M$167.58M$165.10M$163.32M
Shareholders' equity$597.44M$480.36M$501.84M$497.04M$581.40M
Net debt-$39.66M$51.38M$37.45M$36.19M-$42.64M
Cash flow statement
Operating cash flow-$49.95M-$48.46M-$63.27M-$65.78M-$100.75M
Capital expenditure$680,000$271,000$264,000——
Free cash flow-$50.63M-$48.73M-$63.53M——
Investing cash flow$120,000-$97,000-$194,000-$232,000-$1.65M
Financing cash flow$147.34M$40.25M$74.50M-$9.87M$108.53M
Depreciation & amortization$2.46M$4.67M$4.11M$4.38M$4.26M
Stock-based compensation$22.09M$5.87M$3.65M$5.54M$12.51M

Free plan shows the latest 5 periods; Pro shows all 10 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.